| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2023 |
Levan A, Gompertz BP, Salafia OS, Bulla M, Burns E, Hotokezaka K, Izzo L, Lamb GP, Malesani DB, Oates SR, Ravasio ME, Rouco Escorial A, Schneider B, Sarin N, Schulze S, ... ... Dyer MJ, et al. Heavy element production in a compact object merger observed by JWST. Nature. PMID 37879361 DOI: 10.1038/s41586-023-06759-1 |
0.01 |
|
| 2023 |
Caiazzo I, Burdge KB, Tremblay PE, Fuller J, Ferrario L, Gänsicke BT, Hermes JJ, Heyl J, Kawka A, Kulkarni SR, Marsh TR, Mróz P, Prince TA, Richer HB, Rodriguez AC, ... ... Dyer MJ, et al. A rotating white dwarf shows different compositions on its opposite faces. Nature. PMID 37468630 DOI: 10.1038/s41586-023-06171-9 |
0.01 |
|
| 2023 |
Jackson RA, Britton RG, Jayne S, Lehmann S, Cowley CM, Trethewey CS, Smith VM, Schmid R, Fegan C, Walter HS, Dyer MJ. BTK mutations in patients with chronic lymphocytic leukemia (CLL) receiving tirabrutinib. Blood Advances. PMID 37257190 DOI: 10.1182/bloodadvances.2022009366 |
0.01 |
|
| 2021 |
Halford SER, Walter H, McKay P, Townsend W, Linton K, Heinzmann K, Dragoni I, Brotherton L, Veal G, Siskos A, Keun HC, Bacon C, Wedge S, Dyer MJ, Plummer ER. Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Journal of Clinical Oncology. 39: 3115-3115. DOI: 10.1200/JCO.2021.39.15_SUPPL.3115 |
0.01 |
|
| 2020 |
Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, Karlin L, Dyer MJ, Mitra S, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jürgensmeier JM, et al. Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32156743 DOI: 10.1158/1078-0432.Ccr-19-3504 |
0.01 |
|
| 2020 |
Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Patel P, Schwartz-Sagi L, Baek M, Christian B, Dyer MJ, Streetly MJ, Sun CCL, Rule S, et al. Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials. Journal of Clinical Oncology. 38: 8064-8064. DOI: 10.1200/jco.2020.38.15_suppl.8064 |
0.01 |
|
| 2020 |
Townsend W, Buske C, Cartron G, Cunningham D, Dyer MJ, Gribben JG, Zhang Z, Rufibach K, Nielsen T, Herold M, Hiddemann W, Marcus R. Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study. Journal of Clinical Oncology. 38: 8023-8023. DOI: 10.1200/jco.2020.38.15_suppl.8023 |
0.01 |
|
| 2020 |
Karlsson I, Mårtensson L, Borggren M, Kovacek M, Roos C, Blidberg T, Oldham R, Jerkeman M, Dyer MJ, Davies A, Córdoba R, Abrisqueta P, Beers S, Teige I, McAllister A, et al. Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration Blood. 136: 4-5. DOI: 10.1182/blood-2020-138658 |
0.01 |
|
| 2019 |
Patil P, Cieslak A, Bernhart SH, Toprak UH, Wagener R, López C, Wiehle L, Bens S, Altmüller J, Franitza M, Scholz I, Jayne S, Ahearne MJ, Scheffold A, Jebaraj BMC, ... ... Dyer MJ, et al. Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. Genes, Chromosomes & Cancer. PMID 31677197 DOI: 10.1002/gcc.22821 |
0.01 |
|
| 2019 |
Hutchings M, Gritti G, Sureda A, Terol MJ, Dyer MJ, Iacoboni G, Townsend W, Bacac M, Bröske AE, Dimier N, Ferlini C, Keelara A, Lahr A, Lechner K, Moore T, et al. CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Blood. 134: 2871-2871. DOI: 10.1182/blood-2019-123978 |
0.01 |
|
| 2019 |
Allsup D, Lin WY, Fordham SE, Sunter N, Elstob C, Rahman T, Willmore E, Shepherd C, Strathdee G, Barrow T, Mainou-Fowler T, Piddock R, Marr H, Wallis J, Marshall SR, ... ... Dyer MJ, et al. Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia Blood. 134: 1740-1740. DOI: 10.1182/blood-2019-122037 |
0.01 |
|
| 2019 |
Hollebecque A, Assouline S, Samaniego F, You B, Foss F, Prica A, Gordon SW, Webster M, Dyer MJ, El-Sharkawi D, Shapiro GI, Nabell L, Blagden SP, Lister J, Ulahannan SV, et al. Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A072 |
0.01 |
|
| 2019 |
Mehta A, Hollebecque A, Foss F, Lister J, Mita M, Wagner-Johnston N, Dyer M, You B, Prica A, Hernandez-Llizaliturri F, Ferraldeschi R, Chan D, Zhang J, Samaniego F. PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA Hemasphere. 3: 486. DOI: 10.1097/01.HS9.0000562584.48238.C8 |
0.01 |
|
| 2019 |
Samaniego F, Hollebecque A, Foss F, Lister J, Mita M, Wagner-Johnston N, Dyer M, You B, Prica A, Hernandez-Llizaliturri F, Ferraldeschi R, Chan D, Zhang J, Mehta A. PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA Hematological Oncology. 37: 527-527. DOI: 10.1002/Hon.211_2631 |
0.01 |
|
| 2019 |
Karlsson I, Traub S, Järås K, Edwards D, Gramming E, Lindell Andersson M, To Y, Mårtensson L, Teige I, Acton G, Dyer M, Radford J, Collins G, Jerkeman M, Frendéus B, et al. PHASE 1/2A CLINICAL TRIALS OF BI-1206, A MONOCLONAL ANTIBODY TO FCΓRIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B-CELL MALIGNANCIES Hematological Oncology. 37: 520-521. DOI: 10.1002/HON.206_2631 |
0.01 |
|
| 2018 |
Trněný M, Verhoef G, Dyer MJ, Yehuda DB, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, et al. A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. PMID 29748443 DOI: 10.3324/haematol.2017.168401 |
0.01 |
|
| 2018 |
Rule S, Kater AP, Brümmendorf TH, Fegan C, Kaiser M, Radford JA, Stilgenbauer S, Kayser S, Dyer MJ, Brossart P, Cidado J, Drew L, Birkett J, Davies A, Shao W, et al. A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies. Journal of Clinical Oncology. 36: TPS7588-TPS7588. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps7588 |
0.01 |
|
| 2018 |
Dyer MJ, De Vos S, Ruan J, Flowers C, Maddocks KJ, Rule S, Hamdy AM, Izumi R, Slatter JG, Cheung J, Frigualt MM, Wei H, Mourya S, Hunder NNH, Fowler NH. Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology. 36: 7547-7547. DOI: 10.1200/JCO.2018.36.15_SUPPL.7547 |
0.01 |
|
| 2018 |
Townsend W, Buske C, Cartron G, Cunningham D, Dyer MJ, Gribben JG, Hess G, Ishikawa T, Keller U, Kneba M, Malladi R, Neidhart JD, Rusconi C, Zhu J, Catalani O, et al. Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study Blood. 132: 1597-1597. DOI: 10.1182/BLOOD-2018-99-115167 |
0.01 |
|
| 2018 |
Dillon R, Jovanovic J, Potter N, Foot N, Ahearne MJ, Jayne S, Dennis M, Hunter AE, Dyer MJ, Vyas P, Quek L, Russell NH, Hills RK, Solomon E, Grimwade D. Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis Blood. 132: 2570-2570. DOI: 10.1182/BLOOD-2018-99-114233 |
0.01 |
|
| 2018 |
Salles G, Dyer MJ, Hodson DJ, Bouabdallah K, Ysebaert L, Cartron G, Davies AJ, Danilov AV, Fegan C, Kio EA, Huang X, Mitra S, Rule S, Morschhauser F. Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma Blood. 132: 5344-5344. DOI: 10.1182/blood-2018-99-113115 |
0.01 |
|
| 2017 |
Wischhof L, Maida S, Piazzesi A, Gioran A, Barragan Sanz K, Irsen S, Beyer M, Schultze JL, Dyer MJ, Salomoni P, Ehninger D, Nicotera P, Bano D. The SWI/SNF subunit Bcl7a contributes to motor coordination and Purkinje cell function. Scientific Reports. 7: 17055. PMID 29213114 DOI: 10.1038/S41598-017-17284-3 |
0.01 |
|
| 2017 |
Kuriyama K, Enomoto Y, Suzuki R, Watanuki J, Hosoi H, Yamashita Y, Murata S, Mushino T, Tamura S, Hanaoka N, Dyer M, Siebert R, Kiyonari H, Nakakuma H, Kitamura T, et al. Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion. International Journal of Hematology. PMID 29071477 DOI: 10.1007/s12185-017-2360-8 |
0.01 |
|
| 2017 |
Sampson J, O'Regan L, Dyer MJ, Bayliss R, Fry AM. Hsp72 and Nek6 cooperate to cluster amplified centrosomes in cancer cells. Cancer Research. PMID 28720575 DOI: 10.1158/0008-5472.CAN-16-3233 |
0.01 |
|
| 2017 |
Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, ... ... Dyer MJ, et al. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. Blood. PMID 28377400 DOI: 10.1182/Blood-2017-02-765115 |
0.01 |
|
| 2017 |
Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, ... ... Dyer MJ, et al. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications. 8: 14175. PMID 28165464 DOI: 10.1038/Ncomms14175 |
0.01 |
|
| 2017 |
Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase 2 study. Haematologica. PMID 28126962 DOI: 10.3324/haematol.2016.154377 |
0.01 |
|
| 2016 |
Grigg A, Dyer MJ, González Díaz M, Dreyling M, Rule S, Lei G, Knapp A, Wassner-Fritsch E, Marlton P. Safety and efficacy of Obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. PMID 28011903 DOI: 10.3324/haematol.2016.152272 |
0.01 |
|
| 2016 |
Manfroi B, McKee T, Mayol JF, Tabruyn S, Moret S, Villiers C, Righini C, Dyer M, Callanan M, Schneider P, Tzankov A, Matthes T, Sturm N, Huard B. CXCL-8/IL-8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation inducing ligand APRIL. Cancer Research. PMID 27923834 DOI: 10.1158/0008-5472.CAN-16-0786 |
0.01 |
|
| 2016 |
Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. PMID 27802969 DOI: 10.1182/blood-2016-06-715284 |
0.01 |
|
| 2016 |
Samuel J, Jayne S, Chen Y, Majid A, Wignall A, Wormull T, Najeeb H, Luo J, Jones GD, Macip S, Dyer MJ. Posttranscriptional upregulation of p53 by reactive oxygen species in chronic lymphocytic leukemia. Cancer Research. PMID 27634759 DOI: 10.1158/0008-5472.CAN-16-0843 |
0.01 |
|
| 2016 |
Speedy HE, Kinnersley B, Chubb D, Broderick P, Law PJ, Litchfield K, Jayne S, Dyer MJ, Dearden C, Follows GA, Catovsky D, Houlston RS. Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood. PMID 27528712 DOI: 10.1182/blood-2016-01-695692 |
0.01 |
|
| 2016 |
Chen Y, Germano S, Clements C, Samuel J, Shelmani G, Jayne S, Dyer MJ, Macip S. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia. British Journal of Haematology. PMID 27469405 DOI: 10.1111/bjh.14285 |
0.01 |
|
| 2016 |
Dyer MJ, Hale G, Marcus R, Waldmann H. Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. Leukemia & Lymphoma. 2: 179-93. PMID 27456733 DOI: 10.3109/10428199009053522 |
0.01 |
|
| 2016 |
Walter HS, Jayne S, Mensah P, Miall FM, Lyttelton M, Dyer MJ. Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12. Blood Cancer Journal. 6: e435. PMID 27315112 DOI: 10.1038/bcj.2016.42 |
0.01 |
|
| 2016 |
Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, ... ... Dyer MJ, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. American Journal of Hematology. PMID 27312795 DOI: 10.1002/ajh.24451 |
0.01 |
|
| 2016 |
Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, ... ... Dyer MJ, et al. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications. 7: 11889. PMID 27297662 DOI: 10.1038/ncomms11889 |
0.01 |
|
| 2016 |
Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, ... ... Dyer M, et al. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia. PMID 27282254 DOI: 10.1038/leu.2016.134 |
0.01 |
|
| 2016 |
Walter HS, Salles GA, Dyer MJ. New Agents to Treat Chronic Lymphocytic Leukemia. The New England Journal of Medicine. 374: 2185-6. PMID 27248633 DOI: 10.1056/NEJMc1602674#SA2 |
0.01 |
|
| 2016 |
Zhang E, Cotton VE, Hidalgo-Bravo A, Huang Y, J Bell A, F Jarrett R, Wilkie GS, Davison AJ, P Nacheva E, Siebert R, Majid A, Kelpanides I, Jayne S, Dyer MJ, Royle NJ. HHV-8-unrelated primary effusion-like lymphoma associated with clonal loss of inherited chromosomally-integrated human herpesvirus-6A from the telomere of chromosome 19q. Scientific Reports. 6: 22730. PMID 26947392 DOI: 10.1038/srep22730 |
0.01 |
|
| 2016 |
Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, et al. BRAF inhibition in hairy cell leukemia with low dose vemurafenib. Blood. PMID 26941398 DOI: 10.1182/blood-2015-11-680074 |
0.01 |
|
| 2016 |
López C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, Johansson P, Ritgen M, Baumann T, Aymerich M, Jayne S, Russell RB, Campo E, Dyer MJ, Dürig J, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. British Journal of Haematology. PMID 26917488 DOI: 10.1111/bjh.13952 |
0.01 |
|
| 2016 |
Salles GA, Morschhauser F, Cheson B, Rule SA, Fegan C, Guillaume C, Nelson C, Yang Y, Mitra S, Starodub A, Dyer MJ. Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies Blood. 128: 2961-2961. DOI: 10.1182/Blood.V128.22.2961.2961 |
0.01 |
|
| 2015 |
Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, et al. A phase I clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. PMID 26542378 DOI: 10.1182/Blood-2015-08-664086 |
0.01 |
|
| 2015 |
Salaverria I, Martín-Garcia D, López C, Clot G, García-Aragonés M, Navarro A, Delgado J, Baumann T, Pinyol M, Martin-Guerrero I, Carrió A, Costa D, Queirós AC, Jayne S, Aymerich M, ... ... Dyer MJ, et al. Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. Genes, Chromosomes & Cancer. 54: 668-80. PMID 26305789 DOI: 10.1002/gcc.22277 |
0.01 |
|
| 2015 |
Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Ole? M, Else M, Liu X, S?abicki M, Wu B, Troussard X, Dürig J, Andrulis M, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. PMID 26065650 DOI: 10.1182/Blood-2015-04-643361 |
0.01 |
|
| 2015 |
Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, ... ... Dyer MJ, et al. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. British Journal of Haematology. 170: 40-9. PMID 25825041 DOI: 10.1111/bjh.13380 |
0.01 |
|
| 2015 |
Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmenn P, Trn?ný M, Dyer MJ, Piotrowska M, Kozak T, et al. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. PMID 25769539 DOI: 10.3324/haematol.2014.121459 |
0.01 |
|
| 2015 |
Sava GP, Speedy HE, Di Bernardo MC, Dyer MJ, Holroyd A, Sunter NJ, Marr H, Mansouri L, Deaglio S, Karabon L, Frydecka I, Jamroziak K, Woszczyk D, Juliusson G, Smedby KE, et al. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia. 29: 748-51. PMID 25363670 DOI: 10.1038/leu.2014.311 |
0.01 |
|
| 2015 |
Queirós AC, Villamor N, Clot G, Martinez-Trillos A, Kulis M, Navarro A, Penas EM, Jayne S, Majid A, Richter J, Bergmann AK, Kolarova J, Royo C, Russiñol N, Castellano G, ... ... Dyer MJ, et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia. 29: 598-605. PMID 25151957 DOI: 10.1038/leu.2014.252 |
0.01 |
|
| 2015 |
Sarno J, Davis KL, Savino AM, Bugarin C, Pinto S, Buracchi C, Jager A, Palmi C, Barber RC, Silvestri D, Cazzaniga G, Dyer MJ, Biondi A, Nolan GP, Gaipa G. Mass Cytometry Analysis Dissects CRLF2-Driven Signaling Pathways in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Blood. 126: 906-906. DOI: 10.1182/Blood.V126.23.906.906 |
0.01 |
|
| 2015 |
Flinn IW, Brunvand M, Choi MY, Dyer MJ, Gribben J, Hillmen P, Jones J, Li Y, Mobasher M, Vosganian G, Kipps TJ. Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331) Blood. 126: 494-494. DOI: 10.1182/blood.v126.23.494.494 |
0.01 |
|
| 2015 |
Rose-Zerilli MJJ, Parker H, Larrayoz M, Clifford R, Blakemore S, Edelmann J, Gibson J, Wang J, Ljungstrom V, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, ... ... Dyer MJ, et al. Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia Blood. 126: 365-365. DOI: 10.1182/BLOOD.V126.23.365.365 |
0.01 |
|
| 2015 |
Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Ochman M, Lemonnier F, Viailly P, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, ... ... Dyer MJ, et al. Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study Blood. 126: 129-129. DOI: 10.1182/blood.v126.23.129.129 |
0.01 |
|
| 2015 |
Miklos DB, Coutre S, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer M, Mato AR, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S. Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 21: S82-S83. DOI: 10.1016/J.BBMT.2014.11.097 |
0.01 |
|
| 2014 |
Hondares E, Brown MA, Musset B, Morgan D, Cherny VV, Taubert C, Bhamrah MK, Coe D, Marelli-Berg F, Gribben JG, Dyer MJ, DeCoursey TE, Capasso M. Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. Proceedings of the National Academy of Sciences of the United States of America. 111: 18078-83. PMID 25425665 DOI: 10.1073/pnas.1411390111 |
0.01 |
|
| 2014 |
Sanders L, Jayne S, Kennedy B, Miall F, Aukema SM, Siebert R, Wagner SD, Dyer MJ. A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome. Case Reports in Hematology. 2014: 120714. PMID 25349747 DOI: 10.1155/2014/120714 |
0.01 |
|
| 2014 |
Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, ... Dyer MJ, et al. MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica. 99: 1285-91. PMID 25082786 DOI: 10.3324/haematol.2013.101170 |
0.01 |
|
| 2014 |
Hutchinson CV, Dyer MJ. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. British Journal of Haematology. 166: 12-22. PMID 24749490 DOI: 10.1111/bjh.12895 |
0.01 |
|
| 2014 |
Furtado M, Dyer MJ, Johnson R, Berrow M, Rule S. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial. British Journal of Haematology. 165: 575-8. PMID 24666179 DOI: 10.1111/bjh.12769 |
0.01 |
|
| 2014 |
Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, Maria Murga Penas E, Vater I, Jayne S, Dyer MJ, Schrappe M, Dührsen U, Ammerpohl O, Russell RB, Küppers R, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes, Chromosomes & Cancer. 53: 309-16. PMID 24446122 DOI: 10.1002/gcc.22141 |
0.01 |
|
| 2014 |
Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. The New England Journal of Medicine. 370: 286-8. PMID 24428489 DOI: 10.1056/NEJMc1310849 |
0.01 |
|
| 2014 |
Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature Genetics. 46: 56-60. PMID 24292274 DOI: 10.1038/ng.2843 |
0.01 |
|
| 2014 |
Huang PY, Best OG, Almazi JG, Belov L, Davis ZA, Majid A, Dyer MJ, Pascovici D, Mulligan SP, Christopherson RI. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma. 55: 2085-92. PMID 24289109 DOI: 10.3109/10428194.2013.867486 |
0.01 |
|
| 2014 |
Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, et al. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. British Journal of Haematology. 164: 258-65. PMID 24219359 DOI: 10.1111/bjh.12630 |
0.01 |
|
| 2014 |
Horvilleur E, Sbarrato T, Hill K, Spriggs RV, Screen M, Goodrem PJ, Sawicka K, Chaplin LC, Touriol C, Packham G, Potter KN, Dirnhofer S, Tzankov A, Dyer MJ, Bushell M, et al. A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia. 28: 1092-102. PMID 24135829 DOI: 10.1038/leu.2013.295 |
0.01 |
|
| 2014 |
Huang Y, Hidalgo-Bravo A, Zhang E, Cotton VE, Mendez-Bermudez A, Wig G, Medina-Calzada Z, Neumann R, Jeffreys AJ, Winney B, Wilson JF, Clark DA, Dyer MJ, Royle NJ. Human telomeres that carry an integrated copy of human herpesvirus 6 are often short and unstable, facilitating release of the viral genome from the chromosome. Nucleic Acids Research. 42: 315-27. PMID 24057213 DOI: 10.1093/nar/gkt840 |
0.01 |
|
| 2014 |
Dyer MJ, Macip S. Ask the Experts: Precision medicines: a new era for the treatment of B-cell malignancies International Journal of Hematologic Oncology. 3: 113-116. DOI: 10.2217/IJH.14.9 |
0.01 |
|
| 2014 |
Dyer M, Hutchinson C, Rule S, Shah N, Salles GA, Karlin L, Morschhauser F, Terriou L, Fegan C, Davison A, Cartron G, Saunders A, Honda H, Sharpe J, Yoshizawa T, et al. The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL. Journal of Clinical Oncology. 32: 8553-8553. DOI: 10.1200/Jco.2014.32.15_Suppl.8553 |
0.01 |
|
| 2014 |
Trneny M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, López A, Awan F, Montgomery P, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford JA, Siraudin L, et al. Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887). Journal of Clinical Oncology. 32: 8506-8506. DOI: 10.1200/JCO.2014.32.15_SUPPL.8506 |
0.01 |
|
| 2014 |
Coutre S, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Miklos DB, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S. Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant Blood. 124: 4697-4697. DOI: 10.1182/BLOOD.V124.21.4697.4697 |
0.01 |
|
| 2014 |
Flinn I, Brunvand M, Dyer MJ, Hillman P, Jones J, Lymp J, Elhamy M, Vosganian G, Huang J, Kipps TJ. Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Blood. 124: 4687-4687. DOI: 10.1182/BLOOD.V124.21.4687.4687 |
0.01 |
|
| 2014 |
Sascha D, Pircher A, Andrulis M, Ellert E, Peyrade F, Wendtner C, Follows GA, Dyer MJ, Elter T, Zeiser R, Gaehler A, Herrmann M, Herold M, Dearden C, Glimm H, et al. BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib Blood. 124: 3634-3634. DOI: 10.1182/BLOOD.V124.21.3634.3634 |
0.01 |
|
| 2014 |
Fegan C, Bagshawe J, Salles G, Karlin L, Rule S, Shah N, Morschhauser F, Terriou L, Dyer MJ, Walter H, Hutchinson C, Cartron G, Sharpe J, Duffy K, Nishimura A, et al. The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL) Blood. 124: 3328-3328. DOI: 10.1182/Blood.V124.21.3328.3328 |
0.01 |
|
| 2014 |
Goede V, Engelke A, Fischer K, Lopez Jimenez J, Kuzmin A, Dyer MJ, Le Dû K, Liberati AM, Schlag R, Langerak AW, Ritgen M, Stilgenbauer S, Asikanius E, Humphrey K, Wenger MK, et al. Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study Blood. 124: 3327-3327. DOI: 10.1182/BLOOD.V124.21.3327.3327 |
0.01 |
|
| 2014 |
Dyer MJ, Grigg AP, González Díaz M, Dreyling M, Rule S, Lei G, Wassner-Fritsch E, Fingerle-Rowson G, Marlton PV. Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study Blood. 124: 1743-1743. DOI: 10.1182/BLOOD.V124.21.1743.1743 |
0.01 |
|
| 2013 |
Gewies A, Castineiras-Vilarino M, Ferch U, Jährling N, Heinrich K, Hoeckendorf U, Przemeck GK, Munding M, Groß O, Schroeder T, Horsch M, Karran EL, Majid A, Antonowicz S, Beckers J, ... ... Dyer MJ, et al. Prdm6 is essential for cardiovascular development in vivo. Plos One. 8: e81833. PMID 24278461 DOI: 10.1371/journal.pone.0081833 |
0.01 |
|
| 2013 |
Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. British Journal of Haematology. 163: 139-42. PMID 23826785 DOI: 10.1111/bjh.12457 |
0.01 |
|
| 2013 |
Ahearne MJ, Willimott S, Piñon L, Kennedy DB, Miall F, Dyer MJ, Wagner SD. Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. British Journal of Haematology. 162: 360-70. PMID 23710828 DOI: 10.1111/Bjh.12401 |
0.01 |
|
| 2013 |
Dyer MJ, Vogler M, Samuel J, Jayne S, Wagner S, Pritchard C, Macip S. Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. British Journal of Haematology. 160: 725-33. PMID 23346939 DOI: 10.1111/bjh.12219 |
0.01 |
|
| 2013 |
Dyer MJ. The detection of chromosomal translocations involving the immunoglobulin loci in B-cell malignancies. Methods in Molecular Biology (Clifton, N.J.). 971: 123-33. PMID 23296961 DOI: 10.1007/978-1-62703-269-8_7 |
0.01 |
|
| 2013 |
Ramos-Medina R, Montes-Moreno S, Maestre L, Cañamero M, Rodríguez-Pinilla M, Martínez-Torrecuadrada J, Piris MÁ, Majid A, Dyer MJ, Pulford K, Roncador G. BCL7A protein expression in normal and malignant lymphoid tissues. British Journal of Haematology. 160: 106-9. PMID 23043359 DOI: 10.1111/bjh.12080 |
0.01 |
|
| 2013 |
Shah N, Salles GA, Karlin L, Morschhauser F, Terriou L, Dyer MJ, Hutchinson C, Fegan C, Cartron G, Knurowski T, Wright JG, Saunders AJ, Honda H, Mazur A, Yoshizawa T, et al. A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma Blood. 122: 4397-4397. DOI: 10.1182/Blood.V122.21.4397.4397 |
0.01 |
|
| 2013 |
Samuel JJ, Wignall AH, Najeeb H, Majid A, Jayne S, Jones GD, Macip S, Dyer MJ. Proliferating CLL Cells Express Abundant But Transcriptionally Compromised TP53 Protein Blood. 122: 4134-4134. DOI: 10.1182/BLOOD.V122.21.4134.4134 |
0.01 |
|
| 2012 |
Dyer MJ. Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Therapeutic Advances in Hematology. 3: 199-207. PMID 23606931 DOI: 10.1177/2040620712445329 |
0.01 |
|
| 2012 |
Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, Dyer M, Matutes E, Gonzalez D, Taylor AM, Moss P, Thomas P, Oscier D, Stankovic T. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4524-32. PMID 23091097 DOI: 10.1200/Jco.2011.41.0852 |
0.01 |
|
| 2012 |
Ansell SM, Akasaka T, McPhail E, Manske M, Braggio E, Price-Troska T, Ziesmer S, Secreto F, Fonseca R, Gupta M, Law M, Witzig TE, Dyer MJ, Dogan A, Cerhan JR, et al. t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood. 120: 3949-57. PMID 22966169 DOI: 10.1182/blood-2011-11-389908 |
0.01 |
|
| 2012 |
Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, ... Dyer MJ, et al. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. British Journal of Cancer. 107: 1423-32. PMID 22955849 DOI: 10.1038/bjc.2012.380 |
0.01 |
|
| 2012 |
Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M, Malumbres R, Agirre X, Catarino S, Arteta D, Osaba L, Mollejo M, Hernandez-Rivas JM, Calasanz MJ, Daibata M, Dyer MJ, et al. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. British Journal of Haematology. 158: 712-26. PMID 22816737 DOI: 10.1111/j.1365-2141.2012.09226.x |
0.01 |
|
| 2012 |
Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, Goldin LR, Croft N, Holroyd A, Harris S, Riby J, Serie DJ, Kay NE, Call TG, Bracci PM, ... ... Dyer MJ, et al. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood. 120: 843-6. PMID 22700719 DOI: 10.1182/Blood-2012-03-413591 |
0.01 |
|
| 2012 |
Royo C, Navarro A, Clot G, Salaverria I, Giné E, Jares P, Colomer D, Wiestner A, Wilson WH, Vegliante MC, Fernandez V, Hartmann EM, Trim N, Erber WN, Swerdlow SH, ... ... Dyer MJ, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 26: 1895-8. PMID 22425896 DOI: 10.1038/leu.2012.72 |
0.01 |
|
| 2012 |
Salaverria I, Akasaka T, Gesk S, Szczepanowski M, Burkhardt B, Harder L, Damm-Welk C, Oschlies I, Klapper W, Dyer MJ, Siebert R. The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype. Genes, Chromosomes & Cancer. 51: 338-43. PMID 22420028 DOI: 10.1002/gcc.21919 |
0.01 |
|
| 2012 |
McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M, Marcus R, Montoto S, Ramsay A, Wong WL, Ardeshna K. Guidelines on the investigation and management of follicular lymphoma. British Journal of Haematology. 156: 446-67. PMID 22211428 DOI: 10.1111/j.1365-2141.2011.08969.x |
0.01 |
|
| 2012 |
Pepper C, Majid A, Lin TT, Hewamana S, Pratt G, Walewska R, Gesk S, Siebert R, Wagner S, Kennedy B, Miall F, Davis ZA, Tracy I, Gardiner AC, Brennan P, ... ... Dyer MJ, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British Journal of Haematology. 156: 499-507. PMID 22171799 DOI: 10.1111/j.1365-2141.2011.08974.x |
0.01 |
|
| 2012 |
Skowronska A, Austen B, Powell JE, Weston V, Oscier DG, Dyer MJ, Matutes E, Pratt G, Fegan C, Moss P, Taylor MA, Stankovic T. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica. 97: 142-6. PMID 21933854 DOI: 10.3324/haematol.2011.048827 |
0.01 |
|
| 2012 |
Wasik AM, Gandy MN, McIldowie M, Holder MJ, Chamba A, Challa A, Lewis KD, Young SP, Scheel-Toellner D, Dyer MJ, Barnes NM, Piggott MJ, Gordon J. Enhancing the anti-lymphoma potential of 3, 4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: Mechanisms and pathways to cell death Investigational New Drugs. 30: 1471-1483. PMID 21850491 DOI: 10.1007/s10637-011-9730-5 |
0.01 |
|
| 2012 |
Dyer MJ, Grigg A, González M, Dreyling M, Rule SA, Lei G, Wassner-Fritsch E, Wenger MK, Marlton P. Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000) Blood. 120: 3686-3686. DOI: 10.1182/BLOOD.V120.21.3686.3686 |
0.01 |
|
| 2011 |
Lokireddy P, Dyer MJ. Bilateral subdural hygromas following intrathecal methotrexate. British Journal of Haematology. 155: 536. PMID 21923656 DOI: 10.1111/j.1365-2141.2011.08797.x |
0.01 |
|
| 2011 |
Simpson RC, Dyer MJ, Entwisle J, Harman KE. Positron emission tomography features of hidradenitis suppurativa. The British Journal of Radiology. 84: e164-5. PMID 21750134 DOI: 10.1259/bjr/74184796 |
0.01 |
|
| 2011 |
Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, Haferlach C, Siebert R, Dyer MJ, Asou N, Aburatani H, et al. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia. 25: 1849-56. PMID 21738213 DOI: 10.1038/leu.2011.166 |
0.01 |
|
| 2011 |
Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT, Dyer MJ, Goodall AH, Cohen GM. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood. 117: 7145-54. PMID 21562047 DOI: 10.1182/blood-2011-03-344812 |
0.01 |
|
| 2011 |
Vogler M, Dickens D, Dyer MJ, Owen A, Pirmohamed M, Cohen GM. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochemical and Biophysical Research Communications. 408: 344-9. PMID 21514278 DOI: 10.1016/j.bbrc.2011.04.043 |
0.01 |
|
| 2011 |
Alexandroff AB, Shpadaruk V, Bamford WM, Kennedy DB, Burd R, Dyer MJ. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab. British Journal of Haematology. 154: 419-21. PMID 21480857 DOI: 10.1111/j.1365-2141.2011.08620.x |
0.01 |
|
| 2011 |
Dyer MJ, Ye H, Isaacson PG. Primary lymphoma-like lesions of the uterine cervix; sheep in wolves' clothing. British Journal of Haematology. 153: 791-4. PMID 21410452 DOI: 10.1111/j.1365-2141.2011.08659.x |
0.01 |
|
| 2011 |
Dyer MJ, Majid A, Walewska R, Gesk S, Harder L, Siebert R, Morgan B. Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation. Leukemia Research. 35: e55-7. PMID 21185599 DOI: 10.1016/j.leukres.2010.10.033 |
0.01 |
|
| 2011 |
Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G, Yallop D, Buggins AG, Wagner S, Kennedy BJ, Miall F, Hills R, Devereux S, Oscier DG, Dyer MJ, et al. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leukemia Research. 35: 750-6. PMID 21093051 DOI: 10.1016/j.leukres.2010.10.022 |
0.01 |
|
| 2011 |
Capasso M, DeCoursey TE, Dyer MJ. pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1. Trends in Cell Biology. 21: 20-8. PMID 20961760 DOI: 10.1016/j.tcb.2010.09.006 |
0.01 |
|
| 2011 |
Skowronska A, Ahmed G, Oldreive CE, Oscier D, Parker A, Dyer MJ, Matutes E, Taylor AMR, Moss PA, Stankovic T. Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial Blood. 118: 467-467. DOI: 10.1182/BLOOD.V118.21.467.467 |
0.01 |
|
| 2011 |
Ahearne MJ, Bhuller KS, Hew R, Roncador G, Dyer MJ, Kennedy DB, Miall F, Wagner SD. A Variety of T-Cell Subsets Contribute to CD4+ T-Cell Infiltration in Diffuse Large B-Cell Lymphoma and Both Total CD4+ and CD4+FoxP3+ T-Cell Numbers Predict Clinical Outcome, Blood. 118: 3684-3684. DOI: 10.1182/blood.v118.21.3684.3684 |
0.01 |
|
| 2011 |
Robles EF, Aldaz B, Akasaka T, Pellizzeri LM, Martinez-Anso E, Aguirre X, Prosper F, Martin-Guerrero I, Segura V, Calasanz MJ, Sanchez-Garcia I, Campos-Sanchez E, Cobaleda C, Cresson C, Broccardo C, ... ... Dyer MJ, et al. Homeobox NKX2-3 Is Over-Expressed in Human B-Cell Lymphomas and Drives Marginal Zone B-Cell Lymphomagenesis in Mice Blood. 118: 260-260. DOI: 10.1182/BLOOD.V118.21.260.260 |
0.01 |
|
| 2011 |
Novak AJ, Akasaka T, Manske MK, Braggio E, Price-Troska T, Ziesmer S, Frank S, Fonseca R, Gupta M, Law ME, Witzig TE, Dyer MJ, Dogan A, McPhail E, Cerhan JR, et al. Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression Blood. 118: 1570-1570. DOI: 10.1182/BLOOD.V118.21.1570.1570 |
0.01 |
|
| 2011 |
Sun X, Dyer MJ, Cohen GM. REMOVED: Molecular mechanisms involved in resistance of CLL cells towards ABT-737, a specific BCL-2 inhibitor Toxicology. 290: 111. DOI: 10.1016/J.TOX.2011.09.020 |
0.01 |
|
| 2011 |
Vogler M, Hamali HA, Bampton ET, Dinsdale D, Sun X, Dyer MJ, Goodall AH, Cohen GM. Platelet toxicity induced by the BCL2-inhibitor ABT-263, a novel anti-cancer agent Toxicology. 290: 108. DOI: 10.1016/J.TOX.2011.09.016 |
0.01 |
|
| 2011 |
Seymour JF, Roberts AW, Carney DA, Dyer MJ, Kipps TJ, Hallek M, Bociek RG, Brown JR, Wierda WG, Rai K, Ribeiro de Oliveira M, McKeegan E, Chyla B, Busman T, Krivoshik A, et al. 5.23 Phase 2 Study of Navitoclax (ABT-263) Safety and Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Interim Results Clinical Lymphoma Myeloma and Leukemia. 11: S258. DOI: 10.1016/J.CLML.2011.09.177 |
0.01 |
|
| 2011 |
Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Kaderi MA, Rosenquist R, Gaidano G, Dyer M, Söderkvist P, et al. 4.23 MDM2 Promotor Polymorphism and Disease Characteristics in CLL: Individual Patient Data Meta-Analysis of 2598 CLL Patients Clinical Lymphoma Myeloma and Leukemia. 11: S233-S235. DOI: 10.1016/J.CLML.2011.09.143 |
0.01 |
|
| 2011 |
Huang PY, Best OG, Mactier S, Majid A, Dyer M, Mulligan SP, Christopherson RI. 4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia Clinical Lymphoma Myeloma and Leukemia. 11: S221-S222. DOI: 10.1016/J.Clml.2011.09.127 |
0.01 |
|
| 2010 |
Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang L, Irving JA, Wang M, Karran L, Dyer MJ, et al. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. Leukemia. 24: 1817-21. PMID 20739956 DOI: 10.1038/Leu.2010.179 |
0.01 |
|
| 2010 |
Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 116: 4578-87. PMID 20739657 DOI: 10.1182/blood-2010-01-265769 |
0.01 |
|
| 2010 |
Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4217-25. PMID 20601444 DOI: 10.1158/1078-0432.Ccr-10-0777 |
0.01 |
|
| 2010 |
Pattenden CJ, Mann CD, Metcalfe MS, Dyer M, Lloyd DM. Laparoscopic splenectomy: a personal series of 140 consecutive cases. Annals of the Royal College of Surgeons of England. 92: 398-402. PMID 20487598 DOI: 10.1308/003588410X12664192076133 |
0.01 |
|
| 2010 |
Nagel I, Szczepanowski M, Martín-Subero JI, Harder L, Akasaka T, Ammerpohl O, Callet-Bauchu E, Gascoyne RD, Gesk S, Horsman D, Klapper W, Majid A, Martinez-Climent JA, Stilgenbauer S, Tönnies H, ... Dyer MJ, et al. Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood. 116: 1317-20. PMID 20460502 DOI: 10.1182/blood-2009-09-240440 |
0.01 |
|
| 2010 |
Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, Schrauder A, Moericke A, Izraeli S, Akasaka T, Dyer MJ, Siebert R, Schrappe M, Stanulla M. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 115: 5393-7. PMID 20378752 DOI: 10.1182/blood-2009-11-256131 |
0.01 |
|
| 2010 |
Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R, Majid A, Eldering E, Dyer MJ, Cohen GM. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica. 95: 1510-8. PMID 20378569 DOI: 10.3324/haematol.2010.022368 |
0.01 |
|
| 2010 |
Boyd RS, Dyer MJ, Cain K. Proteomic analysis of B-cell malignancies. Journal of Proteomics. 73: 1804-22. PMID 20346427 DOI: 10.1016/j.jprot.2010.03.010 |
0.01 |
|
| 2010 |
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, ... ... Dyer MJ, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 115: 4393-402. PMID 20194898 DOI: 10.1182/blood-2009-06-225979 |
0.01 |
|
| 2010 |
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1749-55. PMID 20194866 DOI: 10.1200/JCO.2009.25.3187 |
0.01 |
|
| 2010 |
Capasso M, Bhamrah MK, Henley T, Boyd RS, Langlais C, Cain K, Dinsdale D, Pulford K, Khan M, Musset B, Cherny VV, Morgan D, Gascoyne RD, Vigorito E, DeCoursey TE, ... ... Dyer MJ, et al. HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nature Immunology. 11: 265-72. PMID 20139987 DOI: 10.1038/ni.1843 |
0.01 |
|
| 2010 |
Crowther-Swanepoel D, Broderick P, Ma Y, Robertson L, Pittman AM, Price A, Twiss P, Vijayakrishnan J, Qureshi M, Dyer MJ, Matutes E, Dearden C, Catovsky D, Houlston RS. Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Human Molecular Genetics. 19: 1840-5. PMID 20123861 DOI: 10.1093/hmg/ddq044 |
0.01 |
|
| 2010 |
Crowther-Swanepoel D, Broderick P, Di Bernardo MC, Dobbins SE, Torres M, Mansouri M, Ruiz-Ponte C, Enjuanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby KE, ... Dyer MJ, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature Genetics. 42: 132-6. PMID 20062064 DOI: 10.1038/Ng.510 |
0.01 |
|
| 2010 |
Dyer MJ, Akasaka T, Capasso M, Dusanjh P, Lee YF, Karran EL, Nagel I, Vater I, Cario G, Siebert R. Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers? Blood. 115: 1490-9. PMID 20042721 DOI: 10.1182/blood-2009-09-235986 |
0.01 |
|
| 2010 |
Musset B, Capasso M, Cherny VV, Morgan D, Bhamrah M, Dyer MJ, DeCoursey TE. Identification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytes. The Journal of Biological Chemistry. 285: 5117-21. PMID 20037153 DOI: 10.1074/jbc.C109.082727 |
0.01 |
|
| 2010 |
Wierda WG, Kipps TJ, Mayer J, Robak T, Dyer MJ, Furman RR, Hillmen P, Stilgenbauer S, Williams CD, Trneny M, Cartron G, Hernandez-Ilizaliturri FJ, Padmanabhan S, Chan GW, Gupta IV, et al. Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia Blood. 116: 921-921. DOI: 10.1182/BLOOD.V116.21.921.921 |
0.01 |
|
| 2010 |
Jiang X, Grant H, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang L, Irving J, Wang M, Karran L, Dyer MJ, et al. Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype. Blood. 116: 3397-3397. DOI: 10.1182/Blood.V116.21.3397.3397 |
0.01 |
|
| 2010 |
Ansell SM, Akasaka T, Manske M, Price-troska T, Ziesmer S, Braggio E, Fonseca R, Gupta M, Law ME, Witzig TE, Dyer MJ, Dogan A, Novak AJ. A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development Blood. 116: 1999-1999. DOI: 10.1182/blood.v116.21.1999.1999 |
0.01 |
|
| 2009 |
Richardson SJ, Eve HE, Copplestone JA, Dyer MJ, Rule SA. Activity of thalidomide and lenalidomide in mantle cell lymphoma. Acta Haematologica. 123: 21-9. PMID 19907157 DOI: 10.1159/000257990 |
0.01 |
|
| 2009 |
Inoue S, Harper N, Walewska R, Dyer MJ, Cohen GM. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Molecular Cancer Therapeutics. 8: 3088-97. PMID 19887558 DOI: 10.1158/1535-7163.MCT-09-0451 |
0.01 |
|
| 2009 |
Crowther-Swanepoel D, Qureshi M, Dyer MJ, Matutes E, Dearden C, Catovsky D, Houlston RS. Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. Blood. 114: 4843-6. PMID 19812382 DOI: 10.1182/blood-2009-07-235184 |
0.01 |
|
| 2009 |
Morgan D, Capasso M, Musset B, Cherny VV, Ríos E, Dyer MJ, DeCoursey TE. Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis. Proceedings of the National Academy of Sciences of the United States of America. 106: 18022-7. PMID 19805063 DOI: 10.1073/Pnas.0905565106 |
0.01 |
|
| 2009 |
Martin-Subero JI, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, Brüggemann M, Bug S, Calasanz MJ, Deckert M, Dreyling M, Du MQ, Dürig J, Dyer MJ, Fan JB, et al. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. Plos One. 4: e6986. PMID 19750229 DOI: 10.1371/journal.pone.0006986 |
0.01 |
|
| 2009 |
Nagel I, Bug S, Tönnies H, Ammerpohl O, Richter J, Vater I, Callet-Bauchu E, Calasanz MJ, Martinez-Climent JA, Bastard C, Salido M, Schroers E, Martin-Subero JI, Gesk S, Harder L, ... ... Dyer MJ, et al. Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia. 23: 2153-5. PMID 19693093 DOI: 10.1038/leu.2009.149 |
0.01 |
|
| 2009 |
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving J, ... ... Dyer MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 114: 2688-98. PMID 19641190 DOI: 10.1182/blood-2009-03-208397 |
0.01 |
|
| 2009 |
Osterborg A, Foà R, Bezares RF, Dearden C, Dyer MJ, Geisler C, Lin TS, Montillo M, van Oers MH, Wendtner CM, Rai KR. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 23: 1980-8. PMID 19626051 DOI: 10.1038/leu.2009.146 |
0.01 |
|
| 2009 |
Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 114: 2273-9. PMID 19597184 DOI: 10.1182/blood-2009-03-212191 |
0.01 |
|
| 2009 |
Bosanquet AG, Richards SM, Wade R, Else M, Matutes E, Dyer MJ, Rassam SM, Durant J, Scadding SM, Raper SL, Dearden CE, Catovsky D. Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. British Journal of Haematology. 146: 384-95. PMID 19552723 DOI: 10.1111/j.1365-2141.2009.07741.x |
0.01 |
|
| 2009 |
Rivetti di Val Cervo P, Tucci P, Majid A, Lena AM, Agostini M, Bernardini S, Candi E, Cohen G, Nicotera P, Dyer MJ, Melino G. p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood. 113: 6498-9; author reply. PMID 19541840 DOI: 10.1182/blood-2009-02-203174 |
0.01 |
|
| 2009 |
Nagel I, Akasaka T, Klapper W, Gesk S, Böttcher S, Ritgen M, Harder L, Kneba M, Dyer MJ, Siebert R. Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. Haematologica. 94: 1020-3. PMID 19454496 DOI: 10.3324/haematol.2008.000968 |
0.01 |
|
| 2009 |
Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3346-53. PMID 19451441 DOI: 10.1200/JCO.2008.19.9117 |
0.01 |
|
| 2009 |
Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, Cohen GM. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death and Differentiation. 16: 1030-9. PMID 19390557 DOI: 10.1038/cdd.2009.48 |
0.01 |
|
| 2009 |
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, ... ... Dyer MJ, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. The Journal of Clinical Investigation. 119: 1109-23. PMID 19363292 DOI: 10.1172/Jci35660 |
0.01 |
|
| 2009 |
Boyd RS, Jukes-Jones R, Walewska R, Brown D, Dyer MJ, Cain K. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Molecular & Cellular Proteomics : McP. 8: 1501-15. PMID 19346216 DOI: 10.1074/mcp.M800515-MCP200 |
0.01 |
|
| 2009 |
Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ, Hofmann WK, Ogawa S, Koeffler HP. Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica. 94: 518-27. PMID 19278963 DOI: 10.3324/Haematol.2008.001347 |
0.01 |
|
| 2009 |
Rossi M, Inoue S, Walewska R, Knight RA, Dyer MJ, Cohen GM, Melino G. Caspase cleavage of Itch in chronic lymphocytic leukemia cells. Biochemical and Biophysical Research Communications. 379: 659-64. PMID 19073138 DOI: 10.1016/j.bbrc.2008.11.154 |
0.01 |
|
| 2009 |
Vater I, Wagner F, Kreuz M, Berger H, Martín-Subero JI, Pott C, Martinez-Climent JA, Klapper W, Krause K, Dyer MJ, Gesk S, Harder L, Zamo A, Dreyling M, Hasenclever D, et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. British Journal of Haematology. 144: 317-31. PMID 19016712 DOI: 10.1111/J.1365-2141.2008.07443.X |
0.01 |
|
| 2009 |
Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 113: 4403-13. PMID 19008458 DOI: 10.1182/blood-2008-08-173310 |
0.01 |
|
| 2009 |
Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, Dyer MJ, Oscier DG. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 23: 212-4. PMID 18818700 DOI: 10.1038/leu.2008.260 |
0.01 |
|
| 2009 |
Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death and Differentiation. 16: 360-7. PMID 18806758 DOI: 10.1038/cdd.2008.137 |
0.01 |
|
| 2009 |
Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, et al. Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab Clinical Lymphoma and Myeloma. 9: E36. DOI: 10.3816/CLM.2009.N.098 |
0.01 |
|
| 2009 |
Novak AJ, Akasaka T, Manske M, Price-Troska T, Gupta M, Witzig TE, Dyer MJ, Dogan A, Ansell SM. Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription. Blood. 114: 3927-3927. DOI: 10.1182/BLOOD.V114.22.3927.3927 |
0.01 |
|
| 2009 |
Österborg A, Ronn BB, Jewell RC, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, et al. Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab. Blood. 114: 3433-3433. DOI: 10.1182/BLOOD.V114.22.3433.3433 |
0.01 |
|
| 2009 |
Stankovic T, Austen B, Pratt G, Skowronska A, Oscier D, Dyer MJ, Matutes E, Taylor M, Moss P. Increased Frequency of Constitutional PathogenicATM Mutations in CLL Patients Compared to Control Individuals Suggests An Aetiological Role. Blood. 114: 1250-1250. DOI: 10.1182/blood.v114.22.1250.1250 |
0.01 |
|
| 2009 |
Musset B, Capasso M, Cherny VV, Morgan D, Dyer MJ, DeCoursey TE. Identification of Phosphorylation Sites that Activate Voltage Gated Proton Channels in Leukocytes Biophysical Journal. 96: 170a-171a. DOI: 10.1016/J.BPJ.2008.12.790 |
0.01 |
|
| 2008 |
Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman AM, Sunter NJ, Hall AG, Dyer MJ, Matutes E, Dearden C, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nature Genetics. 40: 1204-10. PMID 18758461 DOI: 10.1038/ng.219 |
0.01 |
|
| 2008 |
Crowther-Swanepoel D, Wild R, Sellick G, Dyer MJ, Mauro FR, Cuthbert RJ, Jonsson V, Matutes E, Dearden C, Wiley J, Fuller S, Catovsky D, Houlston RS. Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood. 111: 5691-3. PMID 18424666 DOI: 10.1182/blood-2008-03-142349 |
0.01 |
|
| 2008 |
Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ, Cohen GM. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death and Differentiation. 15: 820-30. PMID 18309326 DOI: 10.1038/cdd.2008.25 |
0.01 |
|
| 2008 |
Inoue S, Walewska R, Dyer MJ, Cohen GM. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia. 22: 819-25. PMID 18239621 DOI: 10.1038/leu.2008.1 |
0.01 |
|
| 2008 |
Marafioti T, Paterson JC, Ballabio E, Reichard KK, Tedoldi S, Hollowood K, Dictor M, Hansmann ML, Pileri SA, Dyer MJ, Sozzani S, Dikic I, Shaw AS, Petrella T, Stein H, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 111: 3778-92. PMID 18218851 DOI: 10.1182/Blood-2007-10-117531 |
0.01 |
|
| 2008 |
Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A, Ibbotson R, Stankovic T, Dyer MJ, Oscier DG. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia. 22: 1456-9. PMID 18200038 DOI: 10.1038/sj.leu.2405092 |
0.01 |
|
| 2008 |
Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Loraine Karran E, Nagel I, Harder L, Claviez A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJ, et al. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 111: 387-91. PMID 17940204 DOI: 10.1182/blood-2007-07-092015 |
0.01 |
|
| 2008 |
Helbling I, Walewska R, Dyer MJ, Bamford M, Harman KE. Erythema annulare centrifugum associated with chronic lymphocytic leukaemia. The British Journal of Dermatology. 157: 1044-5. PMID 17935518 DOI: 10.1111/j.1365-2133.2007.08125.x |
0.01 |
|
| 2008 |
Russell LJ, Capasso M, Vater I, Moorman AV, Akasaka T, Harder L, Heidenreich O, Machado L, Gest S, Strefford JC, Chandrasekaran T, Tönnies H, Majid A, Bernard O, Dyer MJ, et al. IGH@ Translocations Involving the Pseudoautosomal Region 1 (PAR1) of Both Sex Chromosomes Deregulate the Cytokine Receptor-Like Factor 2 (CRLF2) Gene in B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Blood. 112: 787-787. DOI: 10.1182/BLOOD.V112.11.787.787 |
0.01 |
|
| 2008 |
Capasso M, Bhamrah MK, Boyd RS, Cain K, Pulford K, Musset B, Cherny VV, Morgan D, DeCoursey TE, Gascoyne RD, Dyer MJ. The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo Blood. 112: 707-707. DOI: 10.1182/BLOOD.V112.11.707.707 |
0.01 |
|
| 2008 |
Boyd RS, Jukes-Jones R, Walewska R, Brown D, Dyer MJ, Cain K. Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma Blood. 112: 374-374. DOI: 10.1182/blood.v112.11.374.374 |
0.01 |
|
| 2008 |
Osterborg A, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmen A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Kozak T, Chan G, Davis RL, et al. Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial Blood. 112: 328-328. DOI: 10.1182/BLOOD.V112.11.328.328 |
0.01 |
|
| 2008 |
Novak A, Akasaka T, Manske M, Gupta M, Witzig T, Dyer MJ, Dogan A, Remstein E, Ansell S. Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma. Blood. 112: 2251-2251. DOI: 10.1182/BLOOD.V112.11.2251.2251 |
0.01 |
|
| 2008 |
MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. Receptor-selective TRAIL Mutants Target Lymphoid Tumor cells for Apoptosis via TRAIL-R1: Implications for Therapy Toxicology. 253: 6-7. DOI: 10.1016/J.TOX.2008.07.046 |
0.01 |
|
| 2007 |
Dyer M. David Galton--the thesis years Leukemia &Amp; Lymphoma. 48: 2290-2291. PMID 18066992 DOI: 10.1080/10428190701706188 |
0.01 |
|
| 2007 |
Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, Majid A, Dyer M, Siebert R, Taylor AM, Moss PA, Stankovic T. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5448-57. PMID 17968022 DOI: 10.1200/JCO.2007.11.2649 |
0.01 |
|
| 2007 |
Majid A, Tsoulakis O, Walewska R, Gesk S, Siebert R, Kennedy DB, Dyer MJ. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood. 111: 874-7. PMID 17959858 DOI: 10.1182/BLOOD-2007-07-098681 |
0.01 |
|
| 2007 |
Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ, Cohen GM. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. British Journal of Haematology. 139: 568-77. PMID 17922877 DOI: 10.1111/j.1365-2141.2007.06852.x |
0.01 |
|
| 2007 |
Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4505-6. PMID 17906217 DOI: 10.1200/JCO.2007.13.1011 |
0.01 |
|
| 2007 |
Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, et al. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 110: 3326-33. PMID 17687107 DOI: 10.1182/blood-2007-05-091561 |
0.01 |
|
| 2007 |
Walewska R, Majid A, Davis Z, Dusanjh P, Kennedy DB, Oscier DG, Dyer MJ. Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69. Leukemia. 21: 2537-8. PMID 17597803 DOI: 10.1038/sj.leu.2404836 |
0.01 |
|
| 2007 |
Sellmann L, Gesk S, Walter C, Ritgen M, Harder L, Martín-Subero JI, Schroers R, Siemer D, Nückel H, Dyer MJ, Dührsen U, Siebert R, Dürig J, Küppers R. Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. British Journal of Haematology. 138: 217-20. PMID 17593029 DOI: 10.1111/j.1365-2141.2007.06636.x |
0.01 |
|
| 2007 |
Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia. 21: 1773-82. PMID 17525724 DOI: 10.1038/Sj.Leu.2404760 |
0.01 |
|
| 2007 |
Martín-Subero JI, Ibbotson R, Klapper W, Michaux L, Callet-Bauchu E, Berger F, Calasanz MJ, De Wolf-Peeters C, Dyer MJ, Felman P, Gardiner A, Gascoyne RD, Gesk S, Harder L, Horsman DE, et al. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia. 21: 1532-44. PMID 17495977 DOI: 10.1038/sj.leu.2404695 |
0.01 |
|
| 2007 |
Boyd RS, Dyer MJ, Cain K. Proteomic analysis of cell surface membrane proteins in leukemic cells. Methods in Molecular Biology (Clifton, N.J.). 370: 135-46. PMID 17416993 DOI: 10.1007/978-1-59745-353-0_11 |
0.01 |
|
| 2007 |
Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R, Möller P, Barth TF. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes, Chromosomes & Cancer. 46: 406-15. PMID 17243160 DOI: 10.1002/gcc.20420 |
0.01 |
|
| 2007 |
Akasaka T, Balasas T, Russell LJ, Sugimoto KJ, Majid A, Walewska R, Karran EL, Brown DG, Cain K, Harder L, Gesk S, Martin-Subero JI, Atherton MG, Brüggemann M, Calasanz MJ, ... ... Dyer MJ, et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 109: 3451-61. PMID 17170124 DOI: 10.1182/blood-2006-08-041012 |
0.01 |
|
| 2007 |
Davis RF, Dusanjh P, Majid A, Fletcher A, Wardlaw A, Siebert R, Dyer MJ, Harman KE. Eosinophilic cellulitis as a presenting feature of chronic eosinophilic leukaemia, secondary to a deletion on chromosome 4q12 creating the FIP1L1-PDGFRA fusion gene. The British Journal of Dermatology. 155: 1087-9. PMID 17034555 DOI: 10.1111/j.1365-2133.2006.07490.x |
0.01 |
|
| 2007 |
Miall FM, Rye AD, Krarup K, West KP, Hew W, Tyagi R, Lyttelton MP, Kennedy B, Thomas G, Dyer MJ. Ultrasound Guided Core Biopsy of the Spleen in Lymphoma Diagnosis. Blood. 110: 4404-4404. DOI: 10.1182/BLOOD.V110.11.4404.4404 |
0.01 |
|
| 2007 |
Vogler M, Majid A, Walewska R, Dyer MJ, Cohen GM. Marked Sensitivity of Chronic Lymphocytic Leukemia (CLL) to Apoptosis Induced by BCL2 Antagonist ABT-737. Blood. 110: 3105-3105. DOI: 10.1182/BLOOD.V110.11.3105.3105 |
0.01 |
|
| 2007 |
Umana P, Ekkehard M, Peter B, Gabriele K, Ursula P, Suter T, Grau R, Schmidt C, Herter S, Gerdes C, Nopora A, Patre M, Moser S, Sondermann P, Wheat L, ... Dyer MJ, et al. GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo. Blood. 110: 2348-2348. DOI: 10.1182/BLOOD.V110.11.2348.2348 |
0.01 |
|
| 2006 |
Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V, Beltran E, Agirre X, Marugan I, Marín M, Rosenwald A, Sugimoto KJ, Wheat LM, Karran EL, García JF, ... ... Dyer MJ, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 109: 271-80. PMID 16960149 DOI: 10.1182/Blood-2006-06-026500 |
0.01 |
|
| 2006 |
Meredith EJ, Holder MJ, Rosén A, Lee AD, Dyer MJ, Barnes NM, Gordon J. Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 103: 13485-90. PMID 16938864 DOI: 10.1073/pnas.0605993103 |
0.01 |
|
| 2006 |
Schwindt H, Akasaka T, Zühlke-Jenisch R, Hans V, Schaller C, Klapper W, Dyer MJ, Siebert R, Deckert M. Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. Journal of Neuropathology and Experimental Neurology. 65: 776-82. PMID 16896311 DOI: 10.1097/01.jnen.0000229988.48042.ae |
0.01 |
|
| 2006 |
Weniger MA, Pulford K, Gesk S, Ehrlich S, Banham AH, Lyne L, Martin-Subero JI, Siebert R, Dyer MJ, Möller P, Barth TF. Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia. 20: 1880-2. PMID 16871282 DOI: 10.1038/sj.leu.2404324 |
0.01 |
|
| 2006 |
Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Research. 66: 6785-92. PMID 16818655 DOI: 10.1158/0008-5472.CAN-05-4563 |
0.01 |
|
| 2006 |
Wheat LM, Kohlhaas SL, Monbaliu J, De Coster R, Majid A, Walewska RJ, Dyer MJ. Inhibition of bortezomib-induced apoptosis by red blood cell uptake. Leukemia. 20: 1646-9. PMID 16791268 DOI: 10.1038/sj.leu.2404290 |
0.01 |
|
| 2006 |
Inoue S, Twiddy D, Dyer MJ, Cohen GM. Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death and Differentiation. 13: 2160-2. PMID 16729023 DOI: 10.1038/sj.cdd.4401977 |
0.01 |
|
| 2006 |
Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, Pulford K, Banham AH, Stockwin L, Shaffer AL, Staudt LM, Das C, Dyer MJ, Tucker PW. Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Molecular Cancer. 5: 18. PMID 16704730 DOI: 10.1186/1476-4598-5-18 |
0.01 |
|
| 2006 |
Miall FM, Harman K, Kennedy B, Dyer MJ. Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. British Journal of Haematology. 132: 115-6. PMID 16371028 DOI: 10.1111/j.1365-2141.2005.05839.x |
0.01 |
|
| 2006 |
MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Research. 65: 11265-70. PMID 16357130 DOI: 10.1158/0008-5472.CAN-05-2801 |
0.01 |
|
| 2006 |
Dyer MJ, Siebert R. Peripheral T-cell non-Hodgkin's lymphoma NOS: naming of parts. Leukemia. 20: 208-9. PMID 16307012 DOI: 10.1038/sj.leu.2404046 |
0.01 |
|
| 2006 |
Best G, Gardiner A, Ibbotson R, Majid A, Walewska R, Austen B, Stankovic T, Dyer M, Oscier DG. A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL. Blood. 108: 2795-2795. DOI: 10.1182/BLOOD.V108.11.2795.2795 |
0.01 |
|
| 2006 |
Morschhauser F, Leonard JP, Fayad L, Coiffier B, Schuster SJ, Dyer MJ, Petillon M, Coleman M, Bahkti A, Horne H, Xu L, Teoh N, Wegener WA, Goldenberg DM. Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. Blood. 108: 2719-2719. DOI: 10.1182/BLOOD.V108.11.2719.2719 |
0.01 |
|
| 2006 |
Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, Grau R, Schmidt C, Gerdes C, Nopora A, Patre M, Moser S, Sondermann P, Wheat L, Dyer MJ, et al. Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction. Blood. 108: 229-229. DOI: 10.1182/BLOOD.V108.11.229.229 |
0.01 |
|
| 2006 |
deLeeuw RJ, Malloff CA, Kimm LR, Connors JM, Dyer MJ, Gascoyne RD, Lam WL. Clinicopathologic Subtypes of Mantle Cell Lymphoma (MCL) Show Distinct Patterns of Genetic Copy Number Alteration. Blood. 108: 2049-2049. DOI: 10.1182/BLOOD.V108.11.2049.2049 |
0.01 |
|
| 2005 |
Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K. The evolving role of alemtuzumab in management of patients with CLL. Leukemia. 19: 2147-52. PMID 16239912 DOI: 10.1038/sj.leu.2403984 |
0.01 |
|
| 2005 |
Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, O'Nions J, Allday M, Hoffmann I, Crawford D, Griffin B, Farrell PJ, Crook T. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood. 107: 250-6. PMID 16160013 DOI: 10.1182/BLOOD-2005-03-1194 |
0.01 |
|
| 2005 |
Sellick GS, Webb EL, Allinson R, Matutes E, Dyer MJ, Jonsson V, Langerak AW, Mauro FR, Fuller S, Wiley J, Lyttelton M, Callea V, Yuille M, Catovsky D, Houlston RS. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. American Journal of Human Genetics. 77: 420-9. PMID 16080117 DOI: 10.1086/444472 |
0.01 |
|
| 2005 |
Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A, Rosenwald A, Climent J, Martinez JI, Schilhabel M, Karran EL, Gesk S, Esteller M, deLeeuw R, Staudt LM, ... ... Dyer MJ, et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood. 106: 3214-22. PMID 16051735 DOI: 10.1182/Blood-2005-05-2013 |
0.01 |
|
| 2005 |
Poppema S, Kluiver JL, Atayar C, van den Berg A, Rosenwald A, Hummel M, Lenze D, Lammert H, Stein H, Joos S, Barth T, Dyer M, Lichter P, Klein U, Cattoretti G, et al. Report: workshop on mediastinal grey zone lymphoma. European Journal of Haematology. Supplementum. 45-52. PMID 16007868 DOI: 10.1111/J.1600-0609.2005.00454.X |
0.01 |
|
| 2005 |
Karran EL, Sonoki T, Dyer MJ. Cloning of immunoglobulin chromosomal translocations by long-distance inverse polymerase chain reaction. Methods in Molecular Medicine. 115: 217-30. PMID 15998970 DOI: 10.1385/1-59259-936-2:217 |
0.01 |
|
| 2005 |
Meredith EJ, Holder MJ, Chamba A, Challa A, Drake-Lee A, Bunce CM, Drayson MT, Pilkington G, Blakely RD, Dyer MJ, Barnes NM, Gordon J. The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 1187-9. PMID 15870169 DOI: 10.1096/fj.04-3477fje |
0.01 |
|
| 2005 |
Lundin J, Kennedy B, Dearden C, Dyer MJ, Osterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood. 105: 4148-9. PMID 15867423 DOI: 10.1182/BLOOD-2004-11-4314 |
0.01 |
|
| 2005 |
MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, Dyer MJ, Cohen GM. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death and Differentiation. 12: 773-82. PMID 15861184 DOI: 10.1038/sj.cdd.4401649 |
0.01 |
|
| 2005 |
Mestre C, Rubio-Moscardo F, Rosenwald A, Climent J, Dyer MJ, Staudt L, Pinkel D, Siebert R, Martinez-Climent JA. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia. 19: 1082-4. PMID 15815722 DOI: 10.1038/Sj.Leu.2403741 |
0.01 |
|
| 2005 |
Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martín-Subero JI, Nieländer I, Garcia-Conde J, Dyer MJ, Terol MJ, Pinkel D, Martinez-Climent JA. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 105: 4445-54. PMID 15718413 DOI: 10.1182/BLOOD-2004-10-3907 |
0.01 |
|
| 2005 |
Knezevich S, Ludkovski O, Salski C, Lestou V, Chhanabhai M, Lam W, Klasa R, Connors JM, Dyer MJ, Gascoyne RD, Horsman DE. Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia. 19: 659-63. PMID 15716988 DOI: 10.1038/sj.leu.2403661 |
0.01 |
|
| 2005 |
Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death and Differentiation. S193-206. PMID 15608694 DOI: 10.1038/sj.cdd.4401535 |
0.01 |
|
| 2005 |
Ortin M, Bricknell S, Gribben S, Stirrup L, Dyer M, Hunter A. A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and Ifosfamide, Etoposide and Epirubicin (IVE) Plus G-CSF Mobilisation Regimes in Haematological Malignancies. Blood. 106: 5484-5484. DOI: 10.1182/BLOOD.V106.11.5484.5484 |
0.01 |
|
| 2005 |
Wheat LM, Kohlhaas SL, Monbaliu J, De Coster R, Majid A, Walewska RJ, Cohen GM, Dyer MJ. Inhibition of Bortezomib-Induced Apoptosis in Chronic Lymphocytic Leukemia by Red Blood Cell Uptake. Blood. 106: 5027-5027. DOI: 10.1182/BLOOD.V106.11.5027.5027 |
0.01 |
|
| 2005 |
Pulford K, Banham AH, Lyne L, Jones M, Ippolito G, Liu H, Tucker PW, Roncador G, Lucas E, Ashe S, Stockwin E, Walewska R, Karran EL, Gascoyne R, Mason DY, ... Dyer MJ, et al. BCL11AXL Protein: Its Distribution in Normal and Malignant Tissues and Use as a Marker for Plasmacytoid Dendritic Cells. Blood. 106: 4392-4392. DOI: 10.1182/BLOOD.V106.11.4392.4392 |
0.01 |
|
| 2005 |
Dyer MJ, Buckby E, Fermahan P, Walewska R, Kennedy B. Increasing the Dose Intensity of Alemtuzumab (CAMPATH-1H) in Chronic Lymphocytic Leukemia (CLL): The CAM1515 Study. Blood. 106: 2959-2959. DOI: 10.1182/blood.v106.11.2959.2959 |
0.01 |
|
| 2005 |
Dyer MJ, Moser S, Brünker P, Bird P, Almond N, Püentener U, Wheat LM, Bolam E, Berrie E, Grau R, Buckby E, Kennedy B, Stebbings R, Hale G, Umana P. Enhanced Potency of Glycoengineered Anti-CD52 Monoclonal Antibodies (MAbs). Blood. 106: 2958-2958. DOI: 10.1182/BLOOD.V106.11.2958.2958 |
0.01 |
|
| 2005 |
Ortin M, Bricknell S, Kimber J, Stirrup L, Hofer D, Dyer MJ, Hunter A. Harvesting for “A Rainy Day”: A Retrospective Analysis of Its Cost-Effectivenes and Ethical Implications. Blood. 106: 2924-2924. DOI: 10.1182/BLOOD.V106.11.2924.2924 |
0.01 |
|
| 2005 |
Dyer MJ, Akasaka T, Balasas T, Russell L, Sugimoto K, Majid A, Brown DG, Cain K, Strefford JC, Harrison CJ, Siebert R. Involvement of the CEBP Gene Family in Four IGH@ Chromosomal Translocations in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). Blood. 106: 2842-2842. DOI: 10.1182/BLOOD.V106.11.2842.2842 |
0.01 |
|
| 2004 |
Sonoki T, Willis TG, Oscier DG, Karran EL, Siebert R, Dyer MJ. Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR. Leukemia. 18: 2026-31. PMID 15496980 DOI: 10.1038/sj.leu.2403500 |
0.01 |
|
| 2004 |
de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ, Staudt LM, Martinez-Climent JA, Lam WL. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Human Molecular Genetics. 13: 1827-37. PMID 15229187 DOI: 10.1093/Hmg/Ddh195 |
0.01 |
|
| 2004 |
Keating M, Coutré S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma. 4: 220-7. PMID 15072613 DOI: 10.3816/CLM.2004.N.002 |
0.01 |
|
| 2004 |
Inoue S, Snowden RT, Dyer MJ, Cohen GM. CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia. 18: 948-52. PMID 14990979 DOI: 10.1038/sj.leu.2403328 |
0.01 |
|
| 2004 |
Martinez-Climent JA, Rubio-Moscardo F, Climent J, Terol MJ, Sarsotti ET, Benet I, Siebert R, Piris MA, Martin-Subero I, Dyer MJ, Pinkel D, Garcia-Conde J. Mantle Cell Lymphoma Genotypes Identified with CGH to BAC Microarrays Define Clinical Subgroups of Disease and Strongly Predict Patient Outcome. Blood. 104: 695-695. DOI: 10.1182/BLOOD.V104.11.695.695 |
0.01 |
|
| 2004 |
Federico M, Dyer MJ, Caballero MD, Reilly C, Thiel E. The MYOCAN Study. A Phase II Study of Cyclophosphamide, Oncovin, Myocet™, and Prednisone Plus Rituximab (R-COMP) in the Treatment of Elderly Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL). Blood. 104: 4586-4586. DOI: 10.1182/BLOOD.V104.11.4586.4586 |
0.01 |
|
| 2003 |
Snowden RT, Sun XM, Dyer MJ, Cohen GM. Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia. 17: 1981-9. PMID 14513048 DOI: 10.1038/sj.leu.2403088 |
0.01 |
|
| 2003 |
Boyd RS, Adam PJ, Patel S, Loader JA, Berry J, Redpath NT, Poyser HR, Fletcher GC, Burgess NA, Stamps AC, Hudson L, Smith P, Griffiths M, Willis TG, Karran EL, ... ... Dyer MJ, et al. Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B. Leukemia. 17: 1605-12. PMID 12886250 DOI: 10.1038/sj.leu.2402993 |
0.01 |
|
| 2003 |
Weng L, Gesk S, Martín-Subero JI, Harder L, Schlegelberger B, Grote W, Siebert R, Dyer MJ. Interphase cytogenetic characterization of aberrations in the long arm of chromosome 1 in B-cell lymphoid malignancies. Cancer Genetics and Cytogenetics. 144: 83-4. PMID 12810263 DOI: 10.1016/S0165-4608(02)00861-0 |
0.01 |
|
| 2003 |
Dewson G, Snowden RT, Almond JB, Dyer MJ, Cohen GM. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene. 22: 2643-54. PMID 12730678 DOI: 10.1038/sj.onc.1206326 |
0.01 |
|
| 2003 |
Martinez-Climent JA, Sanchez-Izquierdo D, Sarsotti E, Blesa D, Benet I, Climent J, Vizcarra E, Marugan I, Terol MJ, Sole F, Cigudosad JC, Siebert R, Dyer MJ, García-Conde J. Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma. Leukemia & Lymphoma. 44: 459-64. PMID 12688315 DOI: 10.1080/1042819021000055129 |
0.01 |
|
| 2003 |
Nabhan C, Dyer MJ, Rosen ST. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology (Williston Park, N.Y.). 17: 253-62; discussion 2. PMID 12632866 |
0.01 |
|
| 2003 |
Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, Karran L, Marin M, Blesa D, Horsman D, Rosenwald A, Staudt LM, Albertson DG, Du MQ, Ye H, Marynen P, ... ... Dyer MJ, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood. 101: 4539-46. PMID 12560219 DOI: 10.1182/Blood-2002-10-3236 |
0.01 |
|
| 2003 |
Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, Albertson DG, Garcia-Conde J, Dyer MJ, Levy R, Pinkel D, Lossos IS. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood. 101: 3109-17. PMID 12406872 DOI: 10.1182/blood-2002-07-2119 |
0.01 |
|
| 2002 |
Ye H, Liu H, Raderer M, Chott A, Ruskone-Fourmestraux A, Wotherspoon A, Dyer MJ, Chuang SS, Dogan A, Isaacson PG, Du MQ. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 101: 2547-50. PMID 12517817 DOI: 10.1182/blood-2002-10-3167 |
0.01 |
|
| 2002 |
Copie-Bergman C, Boulland ML, Dehoulle C, Möller P, Farcet JP, Dyer MJ, Haioun C, Roméo PH, Gaulard P, Leroy K. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood. 101: 2756-61. PMID 12446450 DOI: 10.1182/BLOOD-2002-07-2215 |
0.01 |
|
| 2002 |
MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH, Cohen GM. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 21: 6809-18. PMID 12360407 DOI: 10.1038/sj.onc.1205853 |
0.01 |
|
| 2002 |
Martín-Subero JI, Harder L, Gesk S, Schlegelberger B, Grote W, Martinez-Climent JA, Dyer MJ, Novo FJ, Calasanz MJ, Siebert R. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. International Journal of Cancer. 98: 470-4. PMID 11920602 DOI: 10.1002/ijc.10169 |
0.01 |
|
| 2002 |
Rye AD, Stitson RN, Dyer MJ. Pituitary infiltration in B-cell chronic lymphocytic leukaemia. British Journal of Haematology. 115: 718. PMID 11843801 DOI: 10.1046/J.1365-2141.2001.03210.X |
0.01 |
|
| 2002 |
Martín-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, Dyer MJ, Siebert R. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 99: 1474-7. PMID 11830502 DOI: 10.1182/Blood.V99.4.1474 |
0.01 |
|
| 2001 |
Martinez-Climent JA, Vizcarra E, Sanchez D, Blesa D, Marugan I, Benet I, Sole F, Rubio-Moscardo F, Terol MJ, Climent J, Sarsotti E, Tormo M, Andreu E, Salido M, Ruiz MA, ... ... Dyer MJ, et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood. 98: 3479-82. PMID 11719392 DOI: 10.1182/BLOOD.V98.12.3479 |
0.01 |
|
| 2001 |
Satterwhite E, Sonoki T, Willis TG, Harder L, Nowak R, Arriola EL, Liu H, Price HP, Gesk S, Steinemann D, Schlegelberger B, Oscier DG, Siebert R, Tucker PW, Dyer MJ. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 98: 3413-20. PMID 11719382 DOI: 10.1182/Blood.V98.12.3413 |
0.01 |
|
| 2001 |
Sonoki T, Harder L, Horsman DE, Karran L, Taniguchi I, Willis TG, Gesk S, Steinemann D, Zucca E, Schlegelberger B, Solé F, Mungall AJ, Gascoyne RD, Siebert R, Dyer MJ. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood. 98: 2837-44. PMID 11675358 DOI: 10.1182/blood.V98.9.2837 |
0.01 |
|
| 2001 |
Meyer C, MacLeod RA, Quentmeier H, Janssen JW, Coignet LJ, Dyer MJ, Drexler HG. Establishment of the B cell precursor acute lymphoblastic leukemia cell line MUTZ-5 carrying a (12:13) translocation. Leukemia. 15: 1471-4. PMID 11516110 DOI: 10.1038/sj.leu.2402212 |
0.01 |
|
| 2000 |
Bertin J, Guo Y, Wang L, Srinivasula SM, Jacobson MD, Poyet JL, Merriam S, Du MQ, Dyer MJ, Robison KE, DiStefano PS, Alnemri ES. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. The Journal of Biological Chemistry. 275: 41082-6. PMID 11053425 DOI: 10.1074/Jbc.C000726200 |
0.01 |
|
| 2000 |
Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 96: 808-22. PMID 10910891 |
0.01 |
|
| 2000 |
Du MQ, Peng H, Liu H, Hamoudi RA, Diss TC, Willis TG, Ye H, Dogan A, Wotherspoon AC, Dyer MJ, Isaacson PG. BCL10 gene mutation in lymphoma. Blood. 95: 3885-90. PMID 10845924 |
0.01 |
|
| 2000 |
Callanan MB, Le Baccon P, Mossuz P, Duley S, Bastard C, Hamoudi R, Dyer MJ, Klobeck G, Rimokh R, Sotto JJ, Leroux D. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 97: 309-14. PMID 10618414 DOI: 10.1073/pnas.97.1.309 |
0.01 |
|
| 2000 |
Willis T, Dyer M. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies Blood. 96: 808-822. DOI: 10.1182/blood.v96.3.808 |
0.01 |
|
| 1999 |
Gill S, Broni J, Jefferies S, Osin P, Kovacs G, Maitland NJ, Eeles R, Edwards SM, Dyer MJ, Willis TG, Cooper CS. BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas. MPT Collaborators, St George's Hospital Collaborators. British Journal of Cancer. 80: 1565-8. PMID 10408398 DOI: 10.1038/sj.bjc.6690561 |
0.01 |
|
| 1999 |
Coignet LJ, Lima CS, Min T, Streubel B, Swansbury J, Telford N, Swanton S, Bowen A, Nagai M, Catovsky D, Fonatsch C, Dyer MJ. Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia. Genes, Chromosomes & Cancer. 25: 222-9. PMID 10379868 DOI: 10.1002/(SICI)1098-2264(199907)25:3<222::AID-GCC4>3.0.CO;2-C |
0.01 |
|
| 1999 |
Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson PG, Dyer MJ. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 96: 35-45. PMID 9989495 DOI: 10.1016/S0092-8674(00)80957-5 |
0.01 |
|
| 1998 |
Vaandrager JW, Schuuring E, Kluin-Nelemans HC, Dyer MJ, Raap AK, Kluin PM. DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Blood. 92: 2871-8. PMID 9763572 DOI: 10.1182/Blood.V92.8.2871.420K08_2871_2878 |
0.01 |
|
| 1998 |
Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML, Dyer MJ. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 91: 1873-81. PMID 9490669 |
0.01 |
|
| 1998 |
Vaandrager J, Schuuring E, Kluin-Nelemans HC, Dyer MJ, Raap AK, Kluin PM. DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma Blood. 92: 2871-2878. DOI: 10.1182/blood.v92.8.2871 |
0.01 |
|
| 1998 |
Willis T, Zalcberg I, Coignet L, Wlodarska I, Stul M, Jadayel D, Bastard C, Treleaven J, Catovsky D, Silva M, Dyer M. Molecular Cloning of Translocation t(1;14)(q21;q32) Defines a Novel Gene (BCL9) at Chromosome 1q21 Blood. 91: 1873-1881. DOI: 10.1182/blood.v91.6.1873.1873_1873_1881 |
0.01 |
|
| 1997 |
Willis TG, Jadayel DM, Coignet LJ, Abdul-Rauf M, Treleaven JG, Catovsky D, Dyer MJ. Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood. 90: 2456-64. PMID 9310498 |
0.01 |
|
| 1997 |
Vorechovský I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC, Foroni L, Hammarström L, Webster AD, Yuille MA. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nature Genetics. 17: 96-9. PMID 9288106 DOI: 10.1038/NG0997-96 |
0.01 |
|
| 1997 |
Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1567-74. PMID 9193354 DOI: 10.1200/JCO.1997.15.4.1567 |
0.01 |
|
| 1997 |
Willis T, Jadayel D, Coignet L, Abdul-Rauf M, Treleaven J, Catovsky D, Dyer M. Rapid Molecular Cloning of Rearrangements of the IGHJ Locus Using Long-Distance Inverse Polymerase Chain Reaction Blood. 90: 2456-2464. DOI: 10.1182/blood.v90.6.2456 |
0.01 |
|
| 1996 |
Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology. 93: 151-3. PMID 8611450 DOI: 10.1046/j.1365-2141.1996.450989.x |
0.01 |
|
| 1996 |
Zani V, Asou N, Jadayel D, Heward J, Shipley J, Nacheva E, Takasuki K, Catovsky D, Dyer M. Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon Blood. 87: 3124-3134. DOI: 10.1182/BLOOD.V87.8.3124.BLOODJOURNAL8783124 |
0.01 |
|
| 1995 |
Shipley J, Williams S, O'Byrne A, Kearney L, Jones T, Young B, Dyer M, Catovsky D, Sheer D, Gusterson B. Characterization of a t(10;11)(p13-14;q14-21) in the monoblastic cell line U937. Genes, Chromosomes & Cancer. 13: 138-42. PMID 7542909 DOI: 10.1002/gcc.2870130211 |
0.01 |
|
| 1995 |
Österborg A, Fassas A, Dyer MJ, Anagnostopoulos A, Pangalis G, Catovsky D, Mellstedt H. TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITH THE HUMANISED CD52 MONOCLONAL ANTIBODY CAMPATH-1H Journal of Immunotherapy. 18: 136. DOI: 10.1097/00002371-199508000-00042 |
0.01 |
|
| 1994 |
Ridge SA, Dyer M, Greaves MF, Wiedemann LM. Lack of MDM2 amplification in human leukaemia. British Journal of Haematology. 86: 407-9. PMID 8199038 DOI: 10.1111/j.1365-2141.1994.tb04754.x |
0.01 |
|
| 1994 |
Nacheva E, Dyer M, Metivier C, Jadayel D, Stranks G, Morilla R, Heward J, Holloway T, O'Connor S, Bevan P. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression Blood. 84: 3422-3428. DOI: 10.1182/BLOOD.V84.10.3422.BLOODJOURNAL84103422 |
0.01 |
|
| 1994 |
Nacheva E, Dyer M, Metivier C, Jadayel D, Stranks G, Morilla R, Heward J, Holloway T, O'Connor S, Bevan P. B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression Blood. 84: 3422-3428. DOI: 10.1182/blood.v84.10.3422.3422 |
0.01 |
|
| 1994 |
Dyer M, Zani V, Lu W, O'Byrne A, Mould S, Chapman R, Heward J, Kayano H, Jadayel D, Matutes E. BCL2 translocations in leukemias of mature B cells Blood. 83: 3682-3688. DOI: 10.1182/BLOOD.V83.12.3682.BLOODJOURNAL83123682 |
0.01 |
|
| 1994 |
Jadayel D, Matutes E, Dyer M, Brito-Babapulle V, Khohkar M, Oscier D, Catovsky D. Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin D1 gene Blood. 83: 3664-3671. DOI: 10.1182/BLOOD.V83.12.3664.BLOODJOURNAL83123664 |
0.01 |
|
| 1993 |
Oscier DG, Gardiner A, Dyer M. t(8;9) in chronic myeloid leukaemia. British Journal of Haematology. 83: 176-7. PMID 8435330 DOI: 10.1111/J.1365-2141.1993.TB04653.X |
0.01 |
|
| 1993 |
Dyer M, Heward J, Zani V, Buccheri V, Catovsky D. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias Blood. 82: 865-871. DOI: 10.1182/blood.v82.3.865.bloodjournal823865 |
0.01 |
|
| 1993 |
Dyer M, Heward J, Zani V, Buccheri V, Catovsky D. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias Blood. 82: 865-871. DOI: 10.1182/BLOOD.V82.3.865.865 |
0.01 |
|
| 1993 |
Buccheri V, Mihaljevic B, Matutes E, Dyer M, Mason D, Catovsky D. mb-1: a new marker for B-lineage lymphoblastic leukemia Blood. 82: 853-857. DOI: 10.1182/BLOOD.V82.3.853.853 |
0.01 |
|
| 1993 |
Nacheva E, Dyer M, Fischer P, Stranks G, Heward J, Marcus R, Grace C, Karpas A. C-MYC translocations in de novo B-cell lineage acute leukemias with t(14;18)(cell lines Karpas 231 and 353) Blood. 82: 231-240. DOI: 10.1182/BLOOD.V82.1.231.BLOODJOURNAL821231 |
0.01 |
|
| 1993 |
Nathan B, Anbazhagan R, Dyer M, Ebbs S, Jayatilake H, Gusterson B. Expression of bcl-2-like immunoreactivity in the normal breast and in breast cancer The Breast. 2: 134-137. DOI: 10.1016/0960-9776(93)90055-K |
0.01 |
|
| 1992 |
Monaghan P, Robertson D, Amos TA, Dyer MJ, Mason DY, Greaves MF. Ultrastructural localization of bcl-2 protein. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 40: 1819-25. PMID 1453000 DOI: 10.1177/40.12.1453000 |
0.01 |
|
| 1990 |
Dyer M, Fischer P, Nacheva E, Labastide W, Karpas A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations Blood. 75: 709-714. DOI: 10.1182/BLOOD.V75.3.709.BLOODJOURNAL753709 |
0.01 |
|
| 1990 |
Dyer M, Fischer P, Nacheva E, Labastide W, Karpas A. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations Blood. 75: 709-714. DOI: 10.1182/blood.v75.3.709.709 |
0.01 |
|
| 1989 |
Dyer M. T-cell receptor delta/alpha rearrangements in lymphoid neoplasms Blood. 74: 1073-1083. DOI: 10.1182/BLOOD.V74.3.1073.BLOODJOURNAL7431073 |
0.01 |
|
| 1989 |
Dyer M. T-cell receptor delta/alpha rearrangements in lymphoid neoplasms Blood. 74: 1073-1083. DOI: 10.1182/blood.v74.3.1073.1073 |
0.01 |
|
| 1989 |
Dyer M, Hale G, Hayhoe F, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype Blood. 73: 1431-1439. DOI: 10.1182/blood.v73.6.1431.bloodjournal7361431 |
0.01 |
|
| 1981 |
Dyer MJ, Hunt SV. Committed T lymphocyte stem cells of rats. Characterization by surface W3/13 antigen and radiosensitivity. The Journal of Experimental Medicine. 154: 1164-77. PMID 6974759 DOI: 10.1084/JEM.154.4.1164 |
0.01 |
|
| Hide low-probability matches. |